http://aroundstars.com/r40/2/
Oxigene (NASDAQ: OXGN), a cancer and eye diseasd drug developer basedin Waltham, has its West Coast office in Sout h San Francisco. Its sharexs closed Monday at $2.18. In a Securitiese and Exchange Commissionfiling Monday, the company said the compensationm deal is “in recognition of the level of services to be providedf by Mr. Shiebler in his capacitgy as chairman during an undefined interikm period following his assumptiom of the dutiesof chairman.” Shieblerf received $46,500 last year as a Shiebler’s stock options vest in equal amounts over four starting one year from the date of the grant.
John who was named Oxigene CEOin October, was supposec to be chairman, according to an SEC filing, assuming his reelectiohn to the board of directorws at the annual shareholder meeting May 28. Oxigenw did not give a reaso n why Shiebler instead of Kollina waselected chairman. Former chairman Joel-Tomas Citron, who did not stand for reelectiomn tothe board, received 2008 directo r compensation of $215,994, including a monthly base salary as part of his employmentt contract. Shiebler, 67, has been a directodr of Oxigenesince 2002. He was the advisorty vice chairman and CEO of the Americasof , the assetg arm of for five years ending in Marcg 2007 and had been president and CEO of .
Shiebler is a principao in two familyinvestment businesses. Oxigene’s former presidenty and CEO, Dr. Richard Chin, steppeed down in October and now headsthe , a nonprofity drug developer in San
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment